Annonce

Log ud Log ind
Log ud Log ind
Formue

Både Pfizer og Modernas vacciner baseret på ny uafprøvet teknologi

Morten W. Langer

mandag 16. november 2020 kl. 20:34

Fra Zerohedge:

Humans have been developing vaccines for centuries.

However, the rush for a vaccine to combat COVID-19 forced scientists to adapt and develop new techniques to try and expedite the global quest for a solution. Now, both Moderna and Pfizer (along with Pfizer’s German partner BioNTech) have released headline data purporting to show their mRNA vaccines to be surprisingly effective.

What’s more, as Moderna revealed on Monday, unwanted side-effects, which were expected to be worse than what emerges following the administration of a flu vaccine, appeared to be surprisingly mild. With the market fixated on the race for a vaccine, Deutsche Bank published an updated guide to where all the major vaccine projects stand just a few days ago.

But the major takeaway from these mRNA vaccines is that they don’t work like the vaccines of yore. Instead of using dead or weakened viral genetic material to provoke an immune response.

As Businessweek explained in its ‘vaccine issue’ published over the summer, Moderna’s mRNA-1273 vaccine consists of a strand of mRNA that tells the body to produce the spike protein the coronavirus uses to latch on to human cells. This strand functions like one side of a zipper: the “teeth” are a sequence of chemical letters that cells read to produce the 1,273 amino acids comprising the famous protein “spikes” that the virus uses to latch on to human cells.

When it works as intended, the vaccine starts producing the proteins soon after injection, prompting the immune system to react and build up protective antibodies against them.

Here’s a helpful graphic from Bloomberg.

So far, at least, the biggest difference between the Pfizer and Moderna vaccines appears to be the headline number, which shows Pfizer’s vaccine to be 90% effective, and Moderna’s to be 94.5% effective. To be sure, there are other important differences between the Pfizer and Moderna vaccines. Here’s a quick roundup of the most glaring differences, courtesy of Bloomberg.

How do the results compare?

What do the two vaccines have in common?

Both shots rely on a technology called messenger RNA that has never been used before to develop an approved vaccine. The approach is designed to transform the body’s own cells into vaccine-making factories. The vaccines instruct cells to make copies of the spike protein of the coronavirus, stimulating the creation of protective antibodies.

How are they different?

Moderna received $955 million from the U.S. Operation Warp Speed program. Pfizer has said it didn’t receive any federal funding to develop its vaccine, though BioNTech got as much as 375 million euros ($444 million) in German government assistance. Still, Pfizer has struck a supply agreement with the U.S. worth nearly $2 billion. The U.S. has agreed to pay up to $1.53 billion to purchase supply of the Moderna shot.

What are the storage and distribution challenges?

After vaccines are approved, the effort to immunize hundreds of millions of people will need to overcome a series of other hurdles. Storage and distribution for some of the products is complex. Pfizer’s vaccine must be stored ultra-cold until a few days before it is used, but can be kept at refrigerator temperatures for as much as five days. Moderna, meanwhile, pointed to new data showing its vaccine is stable at refrigerator temperatures for 30 days, much longer than a previously estimated seven days. It can be kept in freezers over the longer term and doesn’t need the special facilities required for the Pfizer vaccine.

With regulatory approval inching closer, we expect more attention will be paid to the deals being struck by Pfizer, Moderna and the like to sell millions of doses to the US, Europe etc.

To be sure, mRNA vaccines are a new technology, and thus present a double-edged sword: while they have become the first vaccines to show results in the west, many questions about their long-term efficacy and side effects remain. While they may ultimately prove harmless with time, there’s little denying the fact that everyone who receives a vaccine during the first round of testing will be like their own little guinea pig.

[postviewcount]

Relaterede nyheder

Jobannoncer

Senior Accountant – få sparringspartnere fra hele Europa (fuldtid)
Region Syddanmark
Finance Controller – få sparringspartnere fra hele Europa (fuldtid)
Region Syddanmark
Analytisk stærk økonomiprofil med interesse for grøn omstilling
Region Sjælland
Chefkonsulent til finanslovsarbejde i Miljø- og Ligestillingsministeriets departement
Region Hovedstaden
Finance Process Owner/Product Owner til Koncernfinans
Region Hovedstaden
ØKONOMICHEF TIL GLOSTRUP BOLIGSELSKAB
Region Hovedstaden
Region Hovedstaden
Erhvervskonsulent til Erhverv og Iværksætteri i Svendborg Kommune
Region Syd
Er du Midtsjællands stærkeste økonomiansvarlige?
Region Sjælland
International Sales Manager til Salg & Marketing
Region Syddanmark.
CODAN Companies ApS søger en Transfer Pricing Specialist
Region Sjælland
Informationsspecialist til Data Governance
Region Hovedstaden
Medarbejder til vurdering af investeringsejendomme
Region Syd
Business Analyst
Region Sjælland
Økonomikonsulent til BUPL’s økonomienhed
Region Hovedstaden
Strategikonsulent søges til Dansk Erhverv
Region Hovedstaden
Direktør – Destination Kystlandet
Region Midt
Vil du være med til at uddanne Finansøkonomer, Au i finansiel rådgivning og P.ba. i Finans?
Region Sjælland.

Mere fra ØU Formue

Log ind

Har du ikke allerede en bruger? Opret dig her.

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank